It can reduce the sensitivity of esophageal cancer to cisplatin chemotherapy and, when highly expressed, can promote tumor cell proliferation and migration while also chemosensitizing DNA damage and downregulating protein expression through the ATM/ATR-p53 signaling pathway 39. Here, ATR is linked to esophageal cancer.